These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21346550)

  • 1. Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor.
    Grande E; José Díez J; Pachón V; Angeles Vaz M; Longo F; Guillén C; García de Paredes ML; Carrato A
    Anticancer Drugs; 2011 Jun; 22(5):477-9. PubMed ID: 21346550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor.
    Lin LZ; Li P; Chen HR; Pang LJ
    Future Oncol; 2013 Jun; 9(6):909-13. PubMed ID: 23718311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine tumors: treatment updates.
    Khagi S; Saif MW
    JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
    J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
    Valle JW; Faivre S; Hubner RA; Grande E; Raymond E
    Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
    Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
    Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
    Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
    BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
    Krug S; Gress TM; Michl P; Rinke A
    Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
    Yao JC; Lombard-Bohas C; Baudin E; Kvols LK; Rougier P; Ruszniewski P; Hoosen S; St Peter J; Haas T; Lebwohl D; Van Cutsem E; Kulke MH; Hobday TJ; O'Dorisio TM; Shah MH; Cadiot G; Luppi G; Posey JA; Wiedenmann B
    J Clin Oncol; 2010 Jan; 28(1):69-76. PubMed ID: 19933912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
    Bisht S; Feldmann G; Brossart P
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
    Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
    Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors.
    Capozzi M; VON Arx C; DE Divitiis C; Ottaiano A; Tatangelo F; Romano GM; Tafuto S;
    Anticancer Res; 2016 Oct; 36(10):5025-5030. PubMed ID: 27798861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor.
    Valdes-Socin H; Almanza MR; Fernández-Ladreda MT; Daele DV; Polus M; Chavez M; Beckers A
    Arch Endocrinol Metab; 2017; 61(5):506-509. PubMed ID: 28977163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib and everolimus in pancreatic neuroendocrine tumors.
    Procopio G; Pusceddu S; Buzzoni R
    Tumori; 2012; 98(3):394. PubMed ID: 22825518
    [No Abstract]   [Full Text] [Related]  

  • 17. Update on novel therapies for pancreatic neuroendocrine tumors: 2013.
    Dimou A; Syrigos KN; Saif MW
    JOP; 2013 Jul; 14(4):377-80. PubMed ID: 23846931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
    Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
    Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
    Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors.
    Deeks ED; Raymond E
    BioDrugs; 2011 Oct; 25(5):307-16. PubMed ID: 21942915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.